| Literature DB >> 34456192 |
Qingli Bie1,2, Ruixia Zhai3, Yanrong Chen1, Yingao Li1, Na Xie1, Baoyi Wang2, Poyun Yuan2, Xinjie Zhou2, Haiyan Cong4, Xin Chang4, Huabao Xiong5, Bin Zhang1,2.
Abstract
BACKGROUND AND OBJECTIVES: Human umbilical cord mesenchymal stem cells (HUC-MSCs) are promising candidates for cell-based therapy in regenerative medicine or other diseases due to their superior characteristics, including higher proliferation, faster self-renewal ability, lower immunogenicity, a noninvasive harvest procedure, easy expansion in vitro, and ethical access, compared with stem cells from other sources. METHODS ANDEntities:
Keywords: HUC-MSCs; Regenerative medicine; SOX9; Skin
Year: 2021 PMID: 34456192 PMCID: PMC8611311 DOI: 10.15283/ijsc21078
Source DB: PubMed Journal: Int J Stem Cells ISSN: 2005-3606 Impact factor: 2.500
Sequences of real-time PCR primers
| mRNA | Primer | Sequences (5’-3’) | Annealing temperature |
|---|---|---|---|
| Human-IL-8 | Forward | AGCTCTGTGTGAAGGTGCAG | 60℃ |
| Reverse | TCTCAGCCCTCTTCAAAAACTTC | ||
| Human-IL-6 | Forward | TTACAGGGAGAGGGAGCGAT | 60℃ |
| Reverse | TTCTCTTTCGTTCCCGGTGG | ||
| Human-GM-CSF | Forward | TGGCCATGGAAAAGGGACTG | 63℃ |
| Reverse | ACTGAGAGGCTGGTCCATCAGA | ||
| Human-VEGF | Forward | GTGACACCAGCTGTCTCCG | 60℃ |
| Reverse | ACCCGTTGATCAGCAGAAGG | ||
| Human-OCT4 | Forward | TTGAGGCTCTGCAGCTTAG | 60℃ |
| Reverse | GCCGGTTACAGAACCACAC | ||
| Human-SALL4 | Forward | TCGATGGCCAACTTCCTTC | 62℃ |
| Reverse | GAGCGGACTCACACTGGAGA | ||
| LV3-homo-SOX9 | GCATCCTTCAATTTCTGTATA | ||
| LV3NC | TTCTCCGAACGTGTCACGT | ||
| Human-β-actin | Forward | GACCTGTACGCCAACACAGT | 59℃ |
| Reverse | CTCAGGAGGAGCAATGATCT |
Fig. 1Human umbilical cord mesenchymal stem cells. (A) HUC-MSCs growth from human umbilical cord tissue, which were observed on 3∼4 days for culture by inverted microscope. (B) HUC-MSCs fusion reached 80% at one week of culture.
Fig. 2The proliferation and migration abilities of HUC-MSCs transfected with shSOX9 or shControl. (A) CCK-8 Kit detected the proliferation of HUC-MSCs transfected with shSOX9 or shControl. (B) Count the cell number of HUC-MSCs transfected with shSOX9 or shControl at different times. (C) Cloning ability of HUC-MSCs transfected with shSOX9 or shControl. (D) Statistical analysis of the clone number according to figure subpart C (n=3; ***p<0.001). (E) The migration of HUC-MSCs transfected with shSOX9 or shControl. (F) Statistical analysis of the migration number according to figure subpart E (n=3; ***p<0.001).
Fig. 3The expression of cytokines and stemness related genes mRNA in HUC-MSCs transfected with shSOX9 or shControl. qRT-PCR was performed to detect the expression of IL-8 (A), IL-6 (B), GM-CSF (C), VEGF (D),OCT4 (E), SALL4 (F) (n=3; *p<0.05; **p<0.01; ***p<0.001; ns: no statistical difference).
Fig. 4Effects of knockdown SOX9 in HUC-MSCs on repairing in wound injury model of rat. (A) The scar of rat in wound injury model treated with PBS or HUC-MSCs transfected with shcontrol or shsox9 at different timepoints day 1, 5, 9, 12, 15 (n=3). (B) Statistical analysis of scar area in back of rat treated with PBS or HUC-MSCs transfected with shcontrol or shsox9 at different timepoints from day 1, 5, 9, 12, 15 (n=3, ns: no statistical difference).
Fig. 5Evaluate scar healing in rat treated with HUC-MSCs transfected with shSOX9 or shcontrol and PBS. HE staining the wound repair skin tissues of rat treated with PBS or HUC-MSCs transfected with shcontrol or shsox9 (n=3). (B) Statistical analysis the thickness of epidermis and dermis (n=3, ns: no statistical difference). (C) Immunofluorescence staining the expression of CK14, CK18 and ki67 in the wound repair skin tissues of rat treated with PBS or HUC-MSCs transfected with shcontrol or shsox9 (n=3).